Shares of OptiNose Inc (NASDAQ:OPTN) have earned an average recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $27.50.
A number of brokerages have recently weighed in on OPTN. Royal Bank of Canada lowered their price target on OptiNose to $25.00 and set an “outperform” rating on the stock in a report on Thursday, March 7th. Zacks Investment Research downgraded OptiNose from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price target on shares of OptiNose in a report on Monday, February 4th. Finally, ValuEngine downgraded OptiNose from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.
Several hedge funds have recently modified their holdings of OPTN. Bank of New York Mellon Corp raised its stake in OptiNose by 1,054.9% during the second quarter. Bank of New York Mellon Corp now owns 178,289 shares of the company’s stock valued at $4,987,000 after purchasing an additional 162,851 shares in the last quarter. JPMorgan Chase & Co. raised its stake in OptiNose by 39.1% during the third quarter. JPMorgan Chase & Co. now owns 1,874,231 shares of the company’s stock valued at $23,297,000 after purchasing an additional 526,501 shares in the last quarter. BlackRock Inc. raised its stake in OptiNose by 8.0% during the third quarter. BlackRock Inc. now owns 1,076,798 shares of the company’s stock valued at $13,384,000 after purchasing an additional 79,541 shares in the last quarter. FMR LLC raised its stake in shares of OptiNose by 1.1% in the third quarter. FMR LLC now owns 6,183,095 shares of the company’s stock valued at $76,856,000 after acquiring an additional 65,887 shares during the period. Finally, Foresite Capital Management IV LLC raised its stake in shares of OptiNose by 57.1% in the third quarter. Foresite Capital Management IV LLC now owns 1,458,545 shares of the company’s stock valued at $18,130,000 after acquiring an additional 530,000 shares during the period. Institutional investors and hedge funds own 56.90% of the company’s stock.
OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.20. OptiNose had a negative return on equity of 77.32% and a negative net margin of 1,509.87%. The business had revenue of $3.02 million for the quarter, compared to the consensus estimate of $2.60 million. On average, equities research analysts anticipate that OptiNose will post -2.86 EPS for the current year.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Featured Story: How is the LIBOR rate calculated?
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.